A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Partner of Industry and Medical Professionals for Ophthalmic Market Data, Primary Research, Independent Perspective, & Objective Analysis
Latest Reports Latest NewsLatest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 350
Comprehensive Pages
- 40
Competitor Profiles
- 11
IOL Categories Forecasted
- 8
Geographic/Economic Breakouts
2022 IOL Market Report: Global Analysis for 2021 to 2027, April, 2022
The “2022 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs.
Latest Industry News & Trends
8/5/2022
BreakingPharmaRegulationRetina
US FDA Approves Coherus’ Lucentis Biosimilar, Branded Cimerli
Coherus BioSciences announced Aug. 2 that the US FDA had approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection). Cimerli is approved for a...
8/5/2022
BreakingCataractDry EyeGlaucomaPresbyopiaRetinaRevenue
Q2-2022 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Three Others
Regeneron of Tarrytown, New York, reported Aug. 3 that its Q2-2022 US revenue for Eylea was a record $1.62 billion, a 14 percent increase over $1.42 billion in Q2-2021. Regeneron’s collaboration re...
8/5/2022
BreakingGlaucomaRegulationSurgical
Glaukos Gains US FDA 510(k) Clearance for iStent Infinite
Glaukos announced Aug. 3 that it had received 510(k) clearance from the US FDA for its iStent Infinite trabecular micro-bypass system. The iStent Infinite is indicated for use in a standalone proce...
8/5/2022
BreakingClinical TrialRetina
OcuTerra Doses First Patient in Phase II Trial of Topical DR Candidate
OcuTerra Therapeutics announced Aug. 2 that the first patient had been dosed in a Phase II clinical trial evaluating its OTT166 eye drop in adults with moderately severe to severe non-proliferative...
8/8/2022
BreakingPharmaRegulation
US Senate Passes Bill That Allows Medicare to Negotiate Prices for Some Drugs
The US Senate on Aug. 7 passed legislation that empowers Medicare to negotiate prescription drug prices on some drugs starting in 2023. Senators passed the Inflation Reduction Act with a 50-50 part...
8/5/2022
BreakingClinical TrialDry Eye
Aerie Doses First Patient in Phase III COMET-3 Study of its TRPM8 Agonist for Dry Eye
Aerie Pharmaceuticals, maker of Rhopressa and Rocklatan for glaucoma, announced Aug. 1 that it had dosed the first patient in the Phase III COMET-3 study of its AR-15512 ophthalmic solution in dry ...
8/5/2022
BreakingClinical TrialPharmaRetina
EyePoint Doses First Patient in Phase II Trial of EYP-1901 in Wet AMD
EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced Aug. 1 that it had dosed the first patient in the Phase II DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (wet AMD)...
8/5/2022
BreakingClinical TrialGene TherapyRetina
Nanoscope Doses First Patient in Phase II Trial of Optogenetic Stargardt Candidate
Nanoscope Therapeutics announced July 25 that the first patient had been dosed in a Phase II trial of its of its optogenetic monotherapy in Stargardt patients. The Dallas company is advancing Multi...
Physician Surveys
For 20+ years, we have surveyed physicians to provide both physicians & industry professionals unbiased insight into the market.
Complete a Survey
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark Your Performance
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
View Market Insights & Analytics
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayMarket Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Over 500 Clients, Large & Small, Have Trusted Market Scope Data & Analysis
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.